Vaccinex Inc Financials
This page shows Vaccinex Inc (VCNX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Vaccinex still looks like a development-stage enterprise: a $601K revenue base sits beside a research-heavy cost structure that has depended on external financing.
R&D spending was reduced from$16.6M in FY2023 to$12.5M in FY2024. Even so, cash resources kept shrinking from$6.4M in FY2022 to$1.1M in FY2024. With the current ratio down to 0.5x, the cuts did not make the company self-funding; they mainly slowed a model still constrained by near-term liquidity.
The revenue line is not carrying the operating model: FY2024 revenue of
When cash flow was last fully reported, cash burn closely matched reported losses: FY2022 operating cash flow of
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Vaccinex Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Vaccinex Inc's revenue grew 5.4% year-over-year to $601K, a solid pace of expansion. This earns a growth score of 100/100.
Vaccinex Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Vaccinex Inc's current ratio of 0.50 is below the typical benchmark, resulting in a score of 4/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Key Financial Metrics
Earnings & Revenue
Vaccinex Inc generated $601K in revenue in fiscal year 2024. This represents an increase of 5.4% from the prior year.
Vaccinex Inc earned $-8.88 per diluted share (EPS) in fiscal year 2024. This represents an increase of 79.7% from the prior year.
Cash & Balance Sheet
Vaccinex Inc held $1.1M in cash against $0 in long-term debt as of fiscal year 2024.
Vaccinex Inc had 3M shares outstanding in fiscal year 2024. This represents an increase of 199.9% from the prior year.
Margins & Returns
Capital Allocation
Vaccinex Inc invested $12.5M in research and development in fiscal year 2024. This represents a decrease of 24.3% from the prior year.
Vaccinex Inc invested $22K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 67.2% from the prior year.
VCNX Income Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $213K+309.6% | $52K-77.6% | $232K+123.1% | $104K | N/A | $20K | N/A | $550K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.1M-32.6% | $3.2M-18.1% | $3.9M+14.2% | $3.4M | N/A | $4.4M-13.8% | $5.0M+32.5% | $3.8M |
| SG&A Expenses | $1.5M+1.9% | $1.4M-31.1% | $2.1M+16.4% | $1.8M | N/A | $1.5M-26.0% | $2.0M+17.6% | $1.7M |
| Operating Income | N/A | -$4.6M+20.4% | -$5.7M-12.8% | -$5.1M | N/A | -$5.8M+17.6% | -$7.1M-41.9% | -$5.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Income Tax | $0 | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$5.7M-1.8% | -$5.6M-44.5% | -$3.9M | N/A | -$4.9M+30.4% | -$7.1M-42.3% | -$5.0M |
| EPS (Diluted) | N/A | $-2.83+8.7% | $-3.10-5.4% | $-2.94 | N/A | $-15.25 | $-24.54-17.5% | $-20.89 |
VCNX Balance Sheet
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6M-46.5% | $4.9M+105.1% | $2.4M-67.9% | $7.4M+102.9% | $3.6M+41.9% | $2.6M-17.1% | $3.1M-37.0% | $4.9M |
| Current Assets | $2.5M-46.8% | $4.8M+116.0% | $2.2M-69.2% | $7.2M+113.6% | $3.3M+51.8% | $2.2M-17.7% | $2.7M-39.4% | $4.4M |
| Cash & Equivalents | $1.1M-61.9% | $2.9M+1147.2% | $233K-92.2% | $3.0M+93.6% | $1.5M+1108.7% | $127K-93.3% | $1.9M-42.6% | $3.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $838K-14.9% | $985K-5.7% | $1.0M-62.3% | $2.8M+188.8% | $961K+3.0% | $933K+8381.8% | $11K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.1M-17.7% | $6.2M+18.0% | $5.2M+11.0% | $4.7M-20.7% | $5.9M-7.5% | $6.4M+83.2% | $3.5M+40.6% | $2.5M |
| Current Liabilities | $5.1M-17.7% | $6.2M+18.0% | $5.2M+11.2% | $4.7M-20.5% | $5.9M-7.0% | $6.4M+88.1% | $3.4M+46.5% | $2.3M |
| Long-Term Debt | $0 | N/A | N/A | $6K-76.9% | $26K-40.9% | $44K-30.2% | $63K-23.2% | $82K |
| Total Equity | -$2.5M-88.3% | -$1.3M+53.9% | -$2.9M-207.9% | $2.7M+214.9% | -$2.3M+40.3% | -$3.9M-814.7% | -$423K-117.6% | $2.4M |
| Retained Earnings | -$358.6M-0.9% | -$355.2M-1.6% | -$349.5M-1.6% | -$343.8M-1.1% | -$339.9M-1.0% | -$336.6M-1.5% | -$331.7M-2.2% | -$324.6M |
VCNX Cash Flow Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M-22.6% | -$3.2M+27.4% | -$4.4M+4.7% | -$4.6M+40.1% | -$7.7M-150.0% | -$3.1M+43.8% | -$5.5M-9.3% | -$5.0M |
| Capital Expenditures | $0-100.0% | $8K-42.9% | $14K | $0 | $0-100.0% | $18K | $0-100.0% | $49K |
| Free Cash Flow | -$3.9M-22.3% | -$3.2M+27.4% | -$4.4M+4.4% | -$4.6M+40.1% | -$7.7M-148.5% | -$3.1M+43.5% | -$5.5M-8.2% | -$5.1M |
| Investing Cash Flow | $0+100.0% | -$8K+42.9% | -$14K | $0 | $0+100.0% | -$18K | $0+100.0% | -$49K |
| Financing Cash Flow | $2.1M-63.8% | $5.9M+248.4% | $1.7M-72.2% | $6.1M-33.6% | $9.1M+586.6% | $1.3M-67.4% | $4.1M+102.5% | $2.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VCNX Financial Ratios
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -8753.9%-6287.5pp | -2466.4%+2412.5pp | -4878.9% | N/A | -29170.0% | N/A | -906.5% |
| Net Margin | N/A | -11023.1%-8595.9pp | -2427.2%+1320.0pp | -3747.1% | N/A | -24560.0% | N/A | -902.2% |
| Return on Equity | N/A | N/A | N/A | -146.8% | N/A | N/A | N/A | -206.8% |
| Return on Assets | N/A | -118.1%+119.8pp | -237.9%-185.0pp | -52.9% | N/A | -192.0%+36.8pp | -228.8%-127.5pp | -101.4% |
| Current Ratio | 0.50-0.3 | 0.77+0.3 | 0.42-1.1 | 1.52+1.0 | 0.57+0.2 | 0.35-0.4 | 0.79-1.1 | 1.91 |
| Debt-to-Equity | 0.00+4.7 | -4.67-2.8 | -1.83-1.8 | 0.00+0.0 | -0.010.0 | -0.01+0.1 | -0.15-0.2 | 0.03 |
| FCF Margin | -1846.0%+4336.7pp | -6182.7%-4273.6pp | -1909.0%+2544.8pp | -4453.9% | N/A | -15565.0% | N/A | -925.3% |
Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Vaccinex Inc's annual revenue?
Vaccinex Inc (VCNX) reported $601K in total revenue for fiscal year 2024. This represents a 5.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vaccinex Inc's revenue growing?
Vaccinex Inc (VCNX) revenue grew by 5.4% year-over-year, from $570K to $601K in fiscal year 2024.
How much debt does Vaccinex Inc have?
As of fiscal year 2024, Vaccinex Inc (VCNX) had $1.1M in cash and equivalents against $0 in long-term debt.
What are Vaccinex Inc's total assets?
Vaccinex Inc (VCNX) had $2.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Vaccinex Inc's capital expenditures?
Vaccinex Inc (VCNX) invested $22K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Vaccinex Inc spend on research and development?
Vaccinex Inc (VCNX) invested $12.5M in research and development during fiscal year 2024.
What is Vaccinex Inc's current ratio?
Vaccinex Inc (VCNX) had a current ratio of 0.50 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Vaccinex Inc's debt-to-equity ratio?
Vaccinex Inc (VCNX) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
Why is Vaccinex Inc's debt-to-equity ratio negative or unusual?
Vaccinex Inc (VCNX) has negative shareholder equity of -$2.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
How financially healthy is Vaccinex Inc?
Vaccinex Inc (VCNX) scores 34 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.